Active Filter(s):
Details:
The data from the trial showed that early-stage Alzheimer’s patients who were taking Nilvadipine showed less cognitive decline over an 18-month period than patients treated with placebo.
Lead Product(s): Nilvadipine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2020